80 results
8-K
EX-99.1
RVMD
Revolution Medicines Inc
8 May 24
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
4:05pm
presentations at this year’s AACR Annual Meeting that elucidate the basis of this compound’s antitumor activity and safety profile. We have also … Trials
Updated Monotherapy Data and Initiation of Pivotal Trials. The company expects to disclose updated clinical safety, tolerability and antitumor
8-K
EX-99.1
e9uf9cl
26 Feb 24
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
4:04pm
8-K
EX-99.1
7ec073 08xu
9 Jan 24
Results of Operations and Financial Condition
2:15pm
8-K
EX-99.1
xfr 1audv
6 Nov 23
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
4:05pm
425
k1jnxftv2i i7c4xckz
23 Oct 23
Business combination disclosure
6:13am
8-K
EX-99.1
tewf lb0urk
23 Oct 23
Regulation FD Disclosure
6:11am
8-K
htj9iekvk
23 Oct 23
Regulation FD Disclosure
6:11am
8-K
kefvra11veoygjp9l
13 Oct 23
Other Events
11:54am
425
at955jtzw 7q
1 Aug 23
Business combination disclosure
5:24pm
425
me1d4p50
1 Aug 23
Business combination disclosure
5:22pm
425
srv7 8ew9w
1 Aug 23
Business combination disclosure
5:11pm
425
odifvn sigea
1 Aug 23
Business combination disclosure
7:15am
8-K
EX-2.1
9jqmxz6
1 Aug 23
Form of Parent Stockholder Voting Agreement
7:10am